| Aug 14 |
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 12 |
scPharmaceuticals announces non-dilutive financing up to $125M with Perceptive Advisors
|
| Aug 12 |
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
|
| Aug 12 |
scPharmaceuticals gets %125M funding from Perceptive Advisors
|
| Aug 12 |
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
|
| Aug 12 |
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
|
| Aug 12 |
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
|
| Aug 12 |
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
|
| Aug 8 |
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
|
| Jul 25 |
scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease
|
